Viewing nowCombinationOlmesartan Medoxomil and Amlodipine Tablets 5/40 mg
Amlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Withus Pharmaceutical Co., Ltd.

MFDS item code 202001261 · Approved 2020.02.21 · Insurance code 660703340
Treatment of essential hypertension not controlled with monotherapy
This medicine is used to treat patients with essential hypertension whose blood pressure is not adequately controlled with monotherapy of amlodipine or olmesartan medoxomil. These medications work by dilating blood vessels to lower blood pressure and reduce the strain on the heart and blood vessels. They help improve blood pressure control in patients, thereby reducing the risk of complications. It is used for the effective management of blood pressure in patients with essential hypertension.
Administer 1 tablet of this medicine once daily with water, with or without food. If possible, it is recommended to take it at the same time each day (e.g., in the morning). Before administering this medicine, it is recommended to adjust the dose using the individual components (amlodipine or olmesartan medoxomil). However, if blood pressure is not controlled with monotherapy using either component, switching directly to this medicine may be considered. The maximum dose of this medicine is 10/40 milligrams. Since the maximum blood pressure-lowering effect occurs within 2 weeks of administration, adjust the dose at intervals of at least 2 weeks, taking the patient’s blood pressure response into account. The recommended doses are as follows. - 5/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with amlodipine 5 milligrams or olmesartan medoxomil 20 milligrams as monotherapy. - 10/20 milligrams: Administer to patients whose blood pressure is not adequately controlled with olmesartan medoxomil 20 milligrams as monotherapy. - 5/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/20 milligrams. - 10/40 milligrams: Administer to patients whose blood pressure is not adequately controlled with 5/40 milligrams. ∘Patients with renal impairment : This medicine has not been studied in patients with renal impairment. However, the maximum dose of olmesartan medoxomil in patients with mild to moderate renal failure (creatine clearance 20-60mL/min) is 20 milligrams once daily, and use of this medicine is not recommended in patients with moderate to severe renal impairment (e.g., creatinine clearance < 20 mL/min) or in patients on dialysis. Monitoring of potassium and creatinine levels is recommended in patients with moderate renal failure. ∘Patients with reduced effective intravascular volume : In patients who may have reduced effective intravascular volume (Intravascular volume depletion) (e.g., patients taking diuretics, particularly those with renal impairment), it is recommended to initiate treatment at a low dose while carefully monitoring their condition. ∘Patients with hepatic impairment : Use with caution in patients with mild to moderate hepatic impairment. The recommended initial dose of olmesartan medoxomil in patients with moderate hepatic impairment is 10 milligrams once daily, and the maximum dose is 20 milligrams once daily. In patients with hepatic impairment who are already receiving other antihypertensive drugs and/or diuretics, blood pressure and renal function should be closely monitored. This medicine should not be administered to patients with severe hepatic impairment. (See section 2, ‘Patients who must not receive this medicine,’ under Precautions for Use.) ∘Older adults : In general, initiate treatment at a low dose. When adjusting the dose, take the patient’s renal or cardiac function and comorbidities into consideration. Blood pressure should be monitored closely and more frequently in older adults.
Safety and efficacy have not been established in pediatric patients younger than 18 years.
This medication can cause serious harm to the fetus and newborns during the second and third trimesters of pregnancy, so it must be discontinued immediately upon confirmation of pregnancy. Patients with allergies to the active components or similar substances, those who are pregnant or breastfeeding, individuals with severe liver dysfunction or aortic stenosis, those with biliary obstruction, patients undergoing kidney dialysis, individuals with signs of shock, specific diabetes patients, or those with moderate to severe impairment in kidney function should not take this medication. Due to the risk of hypotension in patients with low body fluid or sodium levels, caution is necessary. Rapid vessel dilation may result in hypotension, so patients with severe heart disease should be especially careful. Patients with heart failure or weakened kidney function may experience changes in kidney function or a deterioration of heart conditions when taking this medication, so careful monitoring by healthcare professionals is advised. Various side effects such as dizziness, headache, low blood pressure, indigestion, and edema may occur; if any abnormal symptoms occur, inform a healthcare professional immediately. Particularly, this medication can increase serum potassium levels, thus regular blood tests are necessary for patients with decreased kidney function or at risk of hyperkalemia. During pregnancy, there may be risks to the fetus, so those who are pregnant or planning to become pregnant should consult their doctor, and breastfeeding individuals should carefully consider whether to take this medication or stop breastfeeding. This medication is not recommended for children under 18 years of age, as safety and efficacy in this population have not been established. Elderly patients may be at risk of reduced kidney and liver function; therefore, treatment should start at a low dose and proceed with caution. In cases of overdose, severe hypotension and side effects due to vasodilation may occur, necessitating immediate medical attention. This medication should be stored in a tightly closed container, away from direct sunlight and moisture, and should not be transferred to another container.
Not everyone experiences these, and they can vary from person to person.
This medication should be stored in a tightly closed container to protect it from air and moisture. Additionally, it is advisable to store it at room temperature, between 1°C and 30°C, away from extremes of heat or cold.
Pale yellow round film-coated tablet
30 tablets/box [10 tablets/PTP x 3]
Even with the same ingredient, strength, dosage form and how it is taken can differ.
Viewing nowCombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Withus Pharmaceutical Co., Ltd.
CombinationOlmesartan Medoxomil 20mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 6.944mg
Tablet · Prescription medication · Combination
Korea Daiichi Sankyo Co., Ltd.
CombinationOlmesartan Medoxomil 40mg · Amlodipine Besylate 13.888mg
Tablet · Prescription medication · Combination
Hanmi Daiichi Sankyo Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
Co., Ltd. Sainex
Olmesartan Medoxomil · Amlodipine Besylate
Prescription medication · Combination
SYNEX Co., Ltd.
CombinationAmlodipine Besylate 6.944mg · Olmesartan Medoxomil 40mg
Tablet · Prescription medication · Combination
Huons Co., Ltd.
Even with the same ingredient, the dose and directions can differ by strength and dosage form. Talk to a doctor or pharmacist before switching from a medication you are already taking.
No questions yet.
For anything that needs medical judgment, consult a doctor or pharmacist.
This drug information is based on data provided by the Korea Ministry of Food and Drug Safety.
Consult a doctor or pharmacist for accurate dosage, administration, and usage instructions.